Search results
Results from the WOW.Com Content Network
In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]
Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis. It is a humanized anti-CD20 monoclonal antibody. [8] It targets CD20 marker on B lymphocytes and is an immunosuppressive drug. [10] Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds. [10]
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. [9] It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. [9] It is given by intravenous infusion. [9]
Estradiol cypionate/medroxyprogesterone acetate (EC/MPA), sold under the brand name Cyclofem among others, is a form of combined injectable birth control. [2] It contains estradiol cypionate (EC), an estrogen, and medroxyprogesterone acetate (MPA), a progestin. [2] It is recommended for short-term use and is given once a month by injection into ...
Multiple sclerosis (MS) is an autoimmune disease resulting in damage to the insulating covers of nerve cells in the brain and spinal cord. [3] As a demyelinating disease, MS disrupts the nervous system's ability to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. [13] Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions.
Those who took the highest dose available (2.4 milligrams a week) lost an average of 10.6 percent of their total body weight after 20 weeks. After 68 weeks, they lost almost 15 percent of their ...
As of 2020, the National Average Drug Acquisition Cost (NADAC) in the United States for Avonex was $6,872.94 for a 30 mcg kit. [32] Avonex and Rebif are on the top ten best-selling multiple sclerosis drugs of 2013. [33] It is an example of a specialty drug that would only be available through a specialty pharmacy. This is because it requires a ...